The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) determined that Tecfidera (BG-12) qualifies as a new active substance, extending Biogen’s patent protection on the drug and thus lifting the companies fears for drug development in Europe until at least 2024.
So another orally active agent enters the armory, which can only be good news. More information once the EMA or ProfG posts it
Next issue for the Brits is PRICE and NICE
I want to know will it work in PPMS/SPMS?
Does Active Get in the Brain in MS?